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Abbreviations: aCSF, artificial cerebrospinal fluid; ActD, Actinomycin D; AS, Alazami 
Syndrome; bHLH, basic helix-loop-helix motif; BCS, Bowen-Conradi Syndrome; BP, biological 
function; CC, cellular compartment, CDLS, Cornelia De Lange syndrome; DFC, dense fibrillar 
component; DIV7, day in vitro 7; ECM, extracellular matrix; ER, endoplasmic reticulum; FASP, 
Filter-Aided Sample Preparation; GC, granular component; GFP, green fluorescent protein; GO, 
Gene Ontology; HP, human phenotype; iTRAQ, isobaric Tags for Relative and Absolute 
Quantitation; LARP7, La-related protein 7; MF, molecular function; NeuN, neuronal nuclei; No, 
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red fluorescent protein; RP, ribosomal protein; TCF4, transcription factor 4; TIF1A, 
transcription initiation factor 1A; UBF, upstream binding factor;  UPLC, Ultra Performance 
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Summary. To study nucleolar involvement in brain development, the nuclear and nucleolar 
proteomes from the rat cerebral cortex at postnatal day 7 were analyzed using LC-MS/iTRAQ 
methodology. Data of the analysis are available via ProteomeXchange with identifier 
PXD002188. Among 504 candidate nucleolar proteins, the overrepresented gene ontology terms 
included such cellular compartment categories as “nucleolus”, “ribosome” and “chromatin”. 
Consistent with such classification, the most overrepresented functional gene ontology terms 
were related to RNA metabolism/ribosomal biogenesis, translation, and chromatin organization. 
Sixteen putative nucleolar proteins were associated with neurodevelopmental phenotypes in 
humans. Microcephaly and/or cognitive impairment were the most common phenotypic 
manifestations. While several such proteins have links to ribosomal biogenesis and/or genomic 
stability/chromatin structure (e.g. EMG1, RPL10, DKC1, EIF4A3, FLNA, SMC1, ATRX, 
MCM4, NSD1, LMNA or CUL4B), others including ADAR, LARP7, GTF2I or TCF4 have no 
such connections known. Although neither the Alazami syndrome-associated LARP7 nor the 
Pitt-Hopkins syndrome (PTHS)-associated TCF4 were reported in nucleoli of non-neural cells, in 
neurons, their nucleolar localization was confirmed by immunostaining. In cultured rat 
hippocampal neurons, knockdown of LARP7 reduced both perikaryal ribosome content and 
general protein synthesis. Similar anti-ribosomal/anti-translation effects were observed after 
knockdown of the ribosomal biogenesis factor EMG1 whose deficiency underlies Bowen-
Conradi syndrome. Finally, moderate reduction of ribosome content and general protein 
synthesis followed overexpression of two PTHS mutant variants of TCF4. Therefore, 
dysregulation of ribosomal biogenesis and/or other functions of the nucleolus may disrupt 
neurodevelopment resulting in such phenotypes as microcephaly and/or cognitive impairment.  
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Introduction 
The nucleolus is the largest subnuclear structure and is the center of ribosomal biogenesis 
(1, 2). The RNA-polymerase-1 (Pol1)-mediated transcription of nucleolar rRNA genes is the first 
step of ribosome production that is also essential for establishment and maintenance of the 
nucleolus. In addition, pre-rRNA is processed in the nucleolus into mature rRNA species and 
assembled with tens of ribosomal proteins to form pre-ribosomal subunits (3, 4). This complex 
process requires hundreds of trans-acting factors including proteins and small RNAs. Because 
ribosome production requires many resources, it is highly regulated (2).  
Ribosomes are relatively stable structures with an estimated half life time of several days 
(5). Hence, it is not surprising that a highly active nucleolus is often observed in intensely 
dividing cells which require many new ribosomes (1, 2). Conversely, non-dividing cells usually 
display small nucleoli. However, prominent nucleoli are present in various types of mature 
neurons where initial observations of that structure were reported over 150 years ago (6). 
Moreover, neuronal nucleoli appear to increase in size as the nervous system develops (7-9). 
Given the importance of protein synthesis for neuron biology, including neuritic morphogenesis, 
neurite maintenance, and synaptic plasticity, ribosomal biogenesis may be required to maintain 
and regulate the adequate translation apparatus of a neuron. In support of such a possibility, brain 
derived neurotrophic factor (BDNF), which promotes neuronal morphogenesis, survival, and 
synaptic plasticity, stimulates Pol1-driven transcription (10). Therefore, despite their post-mitotic 
status, neurons may maintain large nucleoli to rapidly produce additional ribosomes in response 
to neurotrophic stimulation.  
 Alternatively, the neuronal nucleolus may be involved in processes that are unrelated to 
ribosome biogenesis. For instance, as proficient ribosome biogenesis is required to suppress the 
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p53 pathway, the nucleolus serves as a cellular stress sensor whose dysfunction triggers the p53-
mediated cell cycle arrest and/or apoptosis (11). The stress sensing ability of the nucleolus has 
been also demonstrated in neurons (12, 13). In addition, the nucleolus is a site of non-ribosomal 
ribonucleoprotein complex biogenesis, including the signal recognition particle or components of 
the splicosome (14). Finally, export and degradation of nuclear proteins, regulated protein 
sequestration, as well as establishment and maintenance of chromatin structure add to the 
expanding list of non-ribosomal functions of the nucleolus (14-17).  
 Proteomic analysis of nucleoli from various types of proliferating cells supports a notion 
of the plurifunctional nucleolus. Initial reports revealed that ribosomal biogenesis factors 
represent about 40-50% of roughly 300 proteins that were found in isolated nucleoli (18-20). 
Improved depth of peptide identification expanded the nucleolar proteome to nearly 700 proteins 
with 25% of them being initially implicated in ribosomal biogenesis (20, 21). However, an RNAi 
screen whose design was based on such extended proteomic data sets uncovered tens of new 
ribosomal biogenesis factors expanding their nucleolar proteome contribution to more than 40% 
(22). Processing of tRNA, mRNA metabolism including splicing, DNA repair, DNA replication, 
chromatin organization, and cell cycle regulation are among other functional categories that are 
abundantly represented in the nucleolar proteome. Hence, analysis of the nucleolar proteome can 
be used to identify potentially novel functions of the nucleolus as well as novel regulators of its 
well established roles such as ribosomal biogenesis.  
 The qualitative proteomic analysis of several human cell lines that were grown under 
diverse conditions suggested that 4500 proteins may be located in human cell nucleoli in various 
cellular contexts (23). However, as nucleolar preparations may also be contaminated by other 
cellular compartments, at least some of these proteins may represent false positive hits (20). 
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Instead, quantitative analysis of nucleolar protein enrichment as compared to other cellular 
compartments provides a more specific approach to identify proteins with a localization 
preference for the nucleolus (24).  
  The functional organization of brain cell nucleoli remains mostly unexplored. In the 
nervous system, neither components nor regulators of the ribosomal biogenesis pathway have 
been systematically investigated with the exception of the Pol1 co-factor TIF1A whose 
knockdown or knockout blocks rRNA transcription in various neuronal populations (12, 13, 25, 
26). Likewise, there is little information on non-ribosomal functions of brain cell nucleoli 
beyond their involvement in the p53 stress response pathway. Therefore, the current study was 
initiated to identify nucleolar proteins of the developing rat brain using quantitative iTRAQ 
proteomics.  
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Experimental Procedures 
Animals. Sprague–Dawley pregnant female rats were purchased from Harlan (Indianapolis, IN, 
USA). For proteomic analysis, three separate litters of neonate rats were used at postnatal day 7 
(P7). The cortical tissue was collected from littermates of both sexes. All animal experiments 
strictly followed the protocols that were approved by the University of Louisville Institutional 
Animal Care and Use and Institutional Biosafety Committees. 
Materials. All reagents were obtained from Sigma (St. Louis, MO), VWR (Radnor, PA), or Life 
Technologies-Invitrogen (Grand Island, NY) unless stated otherwise. 
Nucleolar isolation. Rat neocortical nuclei and nucleoli were purified using a previously 
published procedure with modifications (18) (and 
http://www.lamondlab.com/pdf/noprotocol.pdf, Fig. 1A). For preparation of each set of samples 
5-8 pups from a single litter were used. Pulling at least 5 animals/preparation was necessary to 
obtain sufficient amount of proteins in the nucleolar sample. Three independent 
preparations/sample sets from three different litters were used for the subsequent proteomic 
analysis. All steps were performed on ice or at 4°C. The S2 solution as well as RIPA lysis buffer 
(Santa Cruz Biotechnology, Dallas, TX, #24948; 1xPBS (pH 7.4), 1% NP40, 0.5% sodium 
deoxycholate, 0.1% SDS, 0.04% sodium azide) were supplemented with protease inhibitors. 
Dissected cerebral cortices were placed in the ice-cold artificial cerebral spinal fluid (aCSF, 126 
mM NaCl, 25 mM NaHCO3, 25 mM Glucose, 1.25 mM NaH2PO4-H2O, 2.5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, saturated with 5% CO2) and gently dissociated in a Dounce tissue 
homogenizer by turning the pestle to avoid generation of negative pressure. Cells were pelleted 
at 218 x g, resuspended in aCSF, and applied onto 40 μm nylon Cell Strainer (BD Falcon, 
Franklin Lakes, NJ) to separate tissue chunks and blood vessels. The filtrate was again 
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centrifuged at 218 x g. The cell pellet was re-suspended in 5 ml of hypotonic Buffer A (10 mM 
Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT) and incubated on ice for 5 min. The 
cell suspension was transferred directly to a pre-cooled Dounce tissue homogenizer and 
homogenized by 15 pestle strokes using a tight pestle until approximately 90 % of cells burst. 
After centrifugation at 218 x g for 5 min, whole nuclei were collected from the pellet in 5 ml of 
ice-cold S2 solution (0.35 M Sucrose, 0.5 mM MgCl2). One tenth of the sample was lysed in 1 
ml RIPA buffer and used as a nuclear fraction for further analyses. The rest of the sample was 
sonicated at 40% power in 4 bursts, 10s each with 10s intervals to disrupt approximately 90% of 
nuclei. The suspension was ultracentrifuged at 1430 x g for 5 min. The resulting nucleolar pellet 
was re-suspended in 5 ml ice-cold S2 followed by ultracentrifugation and lysis in 1 ml RIPA. 
The lysates were frozen on dry ice and stored at -80°C. 
Western blotting. Western blotting was performed using standard procedures. The primary 
antibodies were as follows: anti-NeuN (1:1000, Millipore, Billerica, MA ABN78), anti-
nucleophosmin/B23 (1:1000, Sigma #B0556), anti-fibrillarin (1:1000, Abcam, Cambridge, MA, 
AB4566), anti-UBF (1:1000, Santa Cruz Biotechnology, SC-13125), anti-actin (1:1000, Sigma, 
#A4700), anti-β-tubulin (1:1000, Sigma, T5293), anti-LARP7 (1:1000, Abcam, AB105683), 
anti-EMG1 (1:1000, Proteintech Group, 11965-1-AP), anti-GFP (MBL, 1:1000), anti-β-
galactosidase (MP Biomedicals, 1:1000), anti-Tom20 (1:1500, a gift of Dr. Brian Wattenberg, 
University of Louisville, Louisville, KY), anti-calreticulin (1:1000, Enzo); secondary antibodies 
were horseradish peroxidase conjugated. 
Dot blot analysis of protein concentration. Two µl of each sample were spotted onto 
chromatography paper filter (Whatman). After all spots dried (about an hour at RT), the 
membrane was incubated for at least 30 min at RT in fixing solution (40% methanol, 10% glacial 
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acetic acid) on a platform shaker. Next, fixing solution was replaced by Coomassie G250 
staining buffer (0,025% Coomassie, 10% glacial acetic acid) and incubated for at least 3 h. The 
membrane was then incubated with destaining buffer (25% methanol, 10% glacial acetic acid). 
Standard curve spots containing variable amount of BSA were used to estimate protein 
concentration of each sample. 
Mass spectrometry. All the samples were brought to the following reagent concentrations: 2% of 
SDS and 100 mM DTT. Protein concentration was estimated with dot-blot.  and 100 µg of 
protein from each sample was taken for further preparation.  Proteins were denatured and 
reduced at 95ºC for 5 minutes, alkylated with iodacetamide and subsequently digested with 
trypsin (Promega) in filter devices (10 MWCO, Sartorius Stedim) using the Filter-Aided Sample 
Preparation (FASP) method (27). The digestion was performed for 16h at enzyme/protein ratio 
of 1/100. For better compatibility with iTRAQ, we used triethylammonium bicarbonate buffer 
(TEAB, Sigma) instead of ammonium bicarbonate. . Further on, all samples were lyophillized 
and incubated with iTRAQ mass tags as recommended in the manufacturer's protocol (Agilent, 
Santa Clara, CA). iTRAQ 8-plex was used and the labeling pattern was as follows: nuclear 
fractions in channels 113, 115 and 117, nucleolar fractions in channels 114, 116 and 118. After 1 
hour the labeling reaction was stopped by diluting each sample with an appropriate amount of 
sample buffer (8 M urea, 0.2% IPG buffer pH 3–11 NL (GE Healthcare), 0.002% bromophenol 
blue in 50 mM Tris–HCl, pH 8.0). Labeled samples were then pooled, concentrated in a 
Speedvac and fractionated on the IEF strip. The strip was then cut into 18 fractions and from 
each fraction peptides were extracted. Peptide mixtures were analyzed with an LC-MS system, 
composed of a UPLC chromatograph (nanoAcquity, Waters) directly coupled to a Q Exactive 
mass spectrometer (Thermo), working in the data-dependent acquisition mode. 
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Proteomic data analysis. The acquired MS/MS data were pre-processed with Mascot Distiller 
software (v.2.4.3, MatrixScience, Boston, MA) and a search was performed with the Mascot 
Search Engine (MatrixScience, Mascot Server 2.4.1) against the UniProt mouse protein database 
(UniProt 2013_11; 43,236 sequences). To reduce mass errors, the peptide and fragment mass 
tolerance settings were established separately for individual LC-MS/MS runs after a measured 
mass recalibration, as described previously (28). Subsequently, data from individual MS runs 
were merged into a single Mascot search. The parameters were as follows: enzyme - Trypsin, 
missed cleavages - 1, fixed modifications - Carbamidomethyl(C), variable modifications - 
Oxidation (M), quantitation - iTRAQ 8plex, taxonomy - unrestricted, instrument - HCD, parent 
MMD - 5 ppm, fragment MMD - 0.08 Da, Decoy option - active. A statistical assessment of the 
confidence of peptide assignments was based on the target/decoy database search strategy (29). 
This procedure provided q-value estimates for each peptide spectrum match in the dataset. All 
queries with q-values >0.01 were removed from further analysis. A protein was regarded as 
identified confidently when at least two peptides of this protein were found. Proteins identified 
by a subset of peptides from another protein were excluded from the analysis. Proteins that 
exactly matched the same set of peptides were combined into a single group (family). The mass 
calibration and data filtering described above were carried out with MScan software, developed 
in-house (http://proteom.ibb.waw.pl/mscan/). The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository 
(http://www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD002188. In addition, 
detailed peptide/protein identification data are presented as a supplementary material 
(DiffprotOutput.txt and Table S5). 
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Nucleolar classifier. iTRAQ results were also incorporated into features used to create a 
classifier for prediction of nucleolar localization of identified proteins. The Multilayer 
Perceptron neural network-based classifier was constructed using WEKA suite (30). It included 
the following features: iTRAQ protein ratio (each sample pair separately), number of peptides, 
nucleolar localization sequences predicted by the Nod software (31), number of various types of 
amino acids present in protein sequence, length of amino acid sequence, gene ontology and 
interaction data (from the IntAct database) and presence of various protein domains. Out of 
them, the following were selected by the software to perform the classification: iTRAQ protein 
ratio, interaction data, presence of lysine-rich domain (PS50318). The training set – which 
included proteins present in nucleus but not nucleolus and known nucleolar proteins - was 
constructed using published data (32). The classifier achieved 93% of correctly assigned 
instances and precision of 0.88 in cross-validation. Two hundred two proteins identified in all 
preparations were assigned nucleolar localization by the classifier, 88 of which acquired q-value 
below 0.05 in the statistical analysis. The remaining 114 proteins had on average less peptides 
identified (2-5, compared to median of 9 peptides for significantly enriched proteins) but higher 
No/Nu enrichment ratios. 
Gene ontology analysis. Gene ontology analysis was performed with the NCBI’s DAVID 
analysis tool. GO_CC_FAT, GO_BP_FAT, and GO_MF_FAT algorithms were used 
(33)(http://david.abcc.ncifcrf.gov/). The default parameters of the GO enrichment searches were 
used with a count threshold set at 2 and the EASE (p-value) threshold set at 0.1; fold enrichment 
as well as FDR values were displayed in search results. Human phenotype analysis was 
performed with the ToppGene using the ToppFun algorithm (34)(https://toppgene.cchmc.org/).  
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Plasmid DNA. The following plasmids were previously described: pCDNA3.1-based expression 
vectors for human wild type TCF4 B- isoform and its mutants (R580W or R582P) (35); chicken 
β-actin promoter-driven-RFP or GFP (36) and EF1α-LacZ (EF1α promoter-driven β-
galactosidase) (37). To prepare Emg1-EGFP expressing plasmid vector 720 bp-long cDNA 
encoding rat Emg1 was cloned into pEGFP-N1 plasmid with XhoI/BamHI restriction enzymes.  
Cell culture and transfections. Cortical and hippocampal neurons were prepared from newborn 
Sprague–Dawley rats at postnatal day 0 as described (38). Cells were plated onto poly-D-lysine- 
and laminin-coated 12 mm diameter plastic coverslips that were produced in the lab from 
electron microscopy-grade mylar masks (Electron Microscopy Sciences, Hatfield, PA, #50425). 
Cells were grown in Neurobasal medium (supplemented with the B-27 supplement (Invitrogen), 
1 mM L-glutamine, 100 units/ml penicillin, and 0.1 mg/ml streptomycin) half of which was 
changed every other day and transfected on day in vitro 3 (DIV3) or DIV6 using Lipofectamine 
2000 (Invitrogen) as previously described (39). Cerebrocortical astrocyte-enriched glial cultures 
were prepared from neonate rats as reported elsewhere (40).  
Immunostaining. All stainings of cultured neurons were performed following 20 min fixation in 
4% formaldehyde at room temperature followed by permeabilization by 0.5% NP-40 in PBS for 
15 minutes. The following primary antibodies were used: rabbit anti-NeuN (1:1000, Millipore, 
ABN78), mouse anti-nucleophosmin/B23 (1:750, Sigma #B0556), mouse anti-fibrillarin (1:750, 
Abcam AB4566), mouse anti-UBF (1:750, St. Cruz, sc-13125), rabbit anti-LARP7 (1:100, 
Abcam, AB105682) and rabbit anti-TCF4 (1:100, Abcam AB185736). The following secondary 
antibodies were used Alexa Fluor 488 goat anti-rabbit IgG (1:300, Invitrogen, A11034), Alexa 
Fluor 594 anti-mouse IgG (1:300, Invitrogen, A11005) and Alexa Fluor 555 anti-rabbit IgG 
(1:300, Invitrogen, A21429). Brain tissue was obtained from P7 rats; immersion-fixed in 4% 
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paraformaldehyde for 24h and 20 µm sections were prepared using as previously described (41).    
Antigen recovery was performed by incubating brain sections with 10 mM sodium citrate, 0.05% 
Tween 20, pH 6.0 at 90-95oC for 20 min followed by standard immunostaining protocol. 
Generation of shRNA expression constructs. To generate shRNAs against rat Larp7 and Emg1 
each mRNA sequence was analyzed using shRNA design software 
(rnaidesigner.lifetechnologies.com) followed by off-target exclusion using Blastn (NCBI). 
Oligonucleotides were designed:  
Larp7-1: 5'gatccccgccagtcagcacattcgatttcaagagaatcgaatgtgctgactggcttttta3',  
Larp7-2: 5'gatccccgctaatcaccaaagctgagttcaagagactcagctttggtgattagcttttta3',  
Larp7-3: 5'gatccccggccaaagctaaagaagagttcaagagactcttctttagctttggccttttta3',  
Emg1-1: 5'gatcccccttacgagctactcaactgttcaagagacagttgagtagctcgtaagttttta3',  
Emg1-2: 5'gatccccgaatgtgctcattgaagtgttcaagagacacttcaatgagcacattctttta3' together with their 
complementary counterparts, annealed and subcloned into the pSuper vector (Oligoengine) 
digested with BglII and HindIII. 
Quantitative Reverse Transcriptase PCR (qRT-PCR). Tri Reagent-based (Sigma) RNA isolation, 
cDNA synthesis and quantitative PCR were performed as described previously (12). The 
following oligonucleotide primers were used: bacterial β-galactosidase forward 
5’tactgacgaaacgcctgccagtat3’ and reverse 5’gctgtgccgaaatggtccatcaaa3’; human TCF4-specific 
forward: 5’acttgcttcgatctattctccag3’ and reverse 5’cataattaggagacgatgaggcc3’. The RNA levels 
were analyzed using ΔΔct method. Expression values obtained from triplicate runs of each 
cDNA sample were calculated relative to the triplicate value for the bacterial β-galactosidase 
from the same cDNA preparation. 
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Quantification of ribosomes. Cultured hippocampal neurons were fixed with 4% formaldehyde 
for 20 min. Ribosomes were visualized with the NeuroTrace 500/525 Green Fluorescent Nissl 
Stain (Invitrogen, N21480, 1:500); DNA was counterstained with 2.5 µg/mL Hoechst 33258. To 
control for the specificity of NeuroTrace staining, some coverslips with attached cells were pre-
treated with RNase A (Qiagen, 20 u in PBS, 1h at 37oC). Cells were imaged using a 40x 
objective lens and a Zeiss Axioobserver inverted microscope system. Digitalized pictures were 
captured using the AxioVision software (Zeiss) followed by conversion to gray scale TIFF files. 
Identical exposure times were used for all pictures that were used for comparative analyses. 
Quantification of the fluorescence intensity was prepared by using the „Integrated Density” 
parameter in the ImageJ software with background correction.  
Protein synthesis assay. To visualize protein synthesis in individual neurons O-propargyl-
puromycin (OPP) labeling method was used followed by Click-iT chemistry detection of nascent 
peptides (42). A commercial kit was employed according to manufacturer’s recommendations 
(Click-iT Plus OPP Alexa Fluor 594 Protein Synthesis Assay Kit, Molecular Probes, C10457). 
To control for the specificity of OPP staining, some coverslips with attached cells were pre-
treated with cycloheximide (CHX, Sigma, 50 μM, 1h at 37oC). Quantification of newly 
synthesized, OPP-labeled peptides was performed as described for ribosome content analysis. 
Statistical analysis. Statistical analysis of quantitative proteomic results was performed with in-
house software (Diffprot) using the following parameters: data normalization – LOWESS, 
clustering of peptide sets with over 80% similarity, statistics – Wilcoxon test (28). To ensure that 
individual variability between biological replicates is not a major contributor to quantitative 
differences between nucleolar- and nuclear data sets, boxplot analysis of interquartile range and 
principal component analysis of quantitative data from individual samples were performed (Fig. 
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S1). In addition, the Diffprot algorithm penalizes quantitative inconsistencies in control samples, 
which further reduces the risk of obtaining artifacts. Statistical analysis of ribosome content and 
protein synthesis activity was performed using one-way ANOVA that was followed by Fisher’s 
LSD posthoc tests. 
 
Results 
Isolation of brain nucleolar proteins. To obtain the nucleolus-enriched protein fraction, whole 
nuclei were first isolated from the neocortex of P7 rats (Fig. 1). Then, nucleoli were obtained 
from the whole nuclei by sonication and ultracentrifugation in sucrose solution (Fig. 1). Relative 
purity of the isolated whole nuclei- and nucleoli was verified by phase contrast microscopy (Fig. 
2A-B). Immunofluorescence for the nucleolar markers fibrillarin and nucleophosmin/B23 (Npm) 
confirmed successful isolation of the nucleoli (Fig. 2C). Sixty one % of the nuclei from which 
nucleoli were isolated were of neuronal origin as determined by the presence of the neuronal 
nuclear marker NeuN (Fig. 2D-E). Importantly, as in P7 cerebral cortex nucleolar presence of 
Npm is disrupted by stressors that interfere with rRNA transcription (41), maintenance of the 
nucleolar Npm staining throughout the nucleolar isolation procedure suggest well preserved 
integrity of the isolated nucleoli (Fig. 2C, E).  
 
Next, protein lysates were prepared and relative nucleolar enrichment was evaluated by 
western blotting for several nucleolar marker proteins including Npm, fibrillarin, and upstream 
binding factor (UBF) (Fig. 3A-B). As compared to the nuclear lysates, all the nucleolar markers 
were enriched in the nucleolar fractions. In addition, relative purity of the nucleolar fraction was 
further verified by western blotting for markers of the cytoskeleton (actin, tubulin), the 
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mitochondrion (Tom20), and, the endoplasmic reticulum (calreticulin). In nucleolar fractions, 
their fibrillarin-normalized signals were 14-50 times lower than in whole cortical lysates (Fig. 
3C). Thus, enriched nucleolar protein samples can be obtained from the cerebral cortex of 
neonate rats.  
 
Proteomic analysis of nucleoli from the developing cerebral cortex. Quantitative proteomics 
using the iTRAQ labeling method was applied to compare samples of intact nuclei and isolated 
nucleoli (Fig. 4A). Three sets of such samples, each prepared independently from different litters 
of neonate rats, were evaluated. Altogether, 3997 proteins were identified (Tables S1 and S5). 
Six hundred forty three proteins were significantly enriched in nucleoli and 487 proteins were 
significantly depleted from this compartment (Table S2, Fig. 4B-C). The gene ontology (GO) 
term “nucleolus” was associated with 12.6% of all nucleolus-enriched proteins (Fig. 4D). That 
fraction increased to 22.9 and 38.3% when the analysis was limited to nucleolar proteins with at 
least 1.5- and 2-fold enrichment, respectively (Fig. 4D).  
  
Next an artificial neural network-based classifier algorithm was built to investigate 
whether apparent but non-significant nucleolar enrichment/depletion of some proteins may 
represent real differences in their subnuclear distribution (see Experimental Procedures for more 
details). Using such an approach, an additional 114 proteins were identified as likely candidates 
for differential nucleolar distribution (Table S3). This set included 102 proteins with apparent 
Nucleolus-enrichment; 75 of them were enriched at least 1.3 fold.  
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Gene ontology analysis of nucleolar proteome from the developing cerebral cortex. For Gene 
Ontology (GO) analysis, a list of candidate nucleolar proteins with a minimum 1.3 fold 
nucleolar-enrichment was prepared by combining significantly enriched proteins (437 of 643) 
with those whose nucleolar enrichment trend was supported by the classifier (75 of 102). For 
simplicity, proteins from this list will be further referred to as nucleolar. 
GO terms associated with the cellular compartment (GO_CC) were assigned to 433 
nucleolar proteins with several GO_CCs being significantly enriched (FDR p<0.05, Table 1, Fig. 
4E). The GO_CC “nucleolus” was assigned to 17% proteins while 9% was associated with 
“ribosome”/“ribosomal subunit”. In addition, 7% proteins were assigned to chromatin-related 
GO_CCs and 3% were splicosomal. Of note, with more than 22% coverage, the GO_CC 
“mitochondrion” had the largest presence among nucleolar proteins of all enriched GO_CCs that 
were organelle/structure specific. Large representation of mitochondrial proteins can be also 
found in other nucleolar proteome data sets that were obtained using similar fractionation 
methodology (21). Indeed, this mitochondrial enrichment appears to be a consequence of 
contamination whose origins are in the whole nuclei fraction (43). In support of that notion, 
similar fold enrichment of mitochondrial proteins was present in nucleolar- and nuclear samples 
from the brain (2.47-, and 1.89 fold, respectively, Table 1). Contamination may also account for 
a smaller, yet significantly enriched group of extracellular matrix/basal membrane components 
(3%, Table 1). Other enriched GO_CC terms were unrelated to a specific subcellular 
organelle/structure and largely overlapped with the aforementioned specific GO_CCs (e.g. 
“ribonucleoprotein complex” , “non-membrane-bounded organelle”, data not shown). Of note, 
30% nucleolar proteins did not associate with any of the enriched GO_CC terms.  
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 Gene ontology terms for Biological Process (GO_BP) were assigned to 411 nucleolar 
proteins. The greatest enrichment was observed for categories related to RNA metabolism 
including “ribosome biogenesis”, “ribonucleoprotein complex biogenesis”, “RNA processing” 
and several other similar terms which all together spanned 17% of the entire nucleolar protein 
list (Table 2, Fig. 4F). “Translation” was another highly enriched GO_BP term followed by 
several GO_BPs that were associated with chromatin organization (e.g.“chromosome 
organization”, “chromatin assembly or disassembly”, “chromatin organization”, “DNA 
packaging” “nucleosome assembly”, “nucleosome organization”). Their contribution to the 
nucleolar proteome was 8 and 9%, respectively. Ten % of the identified proteins were associated 
with mitochondrial GO_BPs (e.g.“cellular respiration”, “generation of precursor metabolites and 
energy”, “electron transport chain” “oxidation reduction” “acetyl-CoA metabolic process”, 
“tricarboxylic acid cycle” and other related terms, Fig. 3C and data not shown). Finally, 53% of 
nucleolar proteins were not associated with any significantly enriched GO_BP.  
 As expected for the center of ribosomal biogenesis, the most Nucleolus-enriched gene 
ontology terms of molecular function (GO_MF) were associated with rRNA binding and 
ribosome structure (Table 3). In addition other enriched GO_MFs included helicases, RNA 
binding proteins, ATPases and nucleotide binding proteins. Taken together, GO analysis 
supports functional specialization of brain cell nucleoli confirming their involvement in 
ribosome synthesis.  
 
Ribosomal proteins of the developing cerebral cortex. Ribosome diversity has been previously 
proposed as a possible mechanism of translational regulation that may be active in the nervous 
system (44). Such a ribosomal diversity may originate from differential use of ribosomal proteins 
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(RPs), as demonstrated for RPL38 (45). In addition, mutations of some ribosomal proteins 
including S3, S4, S15A and L10 have relatively selective impact on forebrain development (46, 
47). In the current data set, 75 nuclear ribosomal proteins were detected (Fig. S2). Of them, 51 
were Nucleolus-enriched (Fig. S2). The abundant nucleolar presence of S3, S4, S15A and L10 
suggests that these RPs are included into newly made brain ribosomes. Interestingly, two pairs of 
RP paralogs were also detected (L7/L7l1 and L22/L22l1). Thus, differential use of these paralogs 
as well as inclusion of S3, S4, S15 and L10 may support ribosomal specialization in the 
developing cerebral cortex.  
 
Human neurological phenotypes associated with nucleolar proteins of the cerebral cortex. 
ToppFun analysis of proteins with a minimum 1.3 fold nucleolus-enrichment revealed significant 
over-representation of such overlapping human phenotype (HP) terms as “Abnormality of the 
cerebellum”, “abnormality of hindbrain morphology”, “abnormality of brain morphology” (FDR 
p<0.05). Of 69 proteins that were in these categories, 48 were associated with GO_CCs 
“mitochondrion” and “ECM part” suggesting that they represent contaminations rather than bona 
fide nucleolar proteins. Three additional potential contaminants were two lysosomal hydrolases 
(NAGA, GLB1) and an ER glycosylase (STT3A). The remaining proteins included 14 whose 
mutations result in neurodevelopmental syndromes (Table 4). Two additional nucleolar proteins 
that are linked to neurodevelopmental disorders were identified by analyzing literature (RPL10 
and EIF4A3, Table 4). Adult onset neurodegeneration was associated with mutations of three 
candidate nucleolar proteins (Table 5).  
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Microcephaly and/or cognitive impairment were the most common elements of the 
neurodevelopmental phenotypes (14 of 16). The target proteins for these phenotypes included a 
ribosomal protein (RPL10), four established ribosomal biogenesis factors (EMG1, DKC1, 
EIF4A3, FLNA), and seven chromatin organization/genome maintenance regulators (SMC1A, 
MCM4, CUL4B, PRKDC, ATRX, NSD1, LMNA). Moreover, neurodevelopmental phenotypes 
were associated with several nucleolus-enriched proteins that did not have any demonstrated 
connections to ribosomal biogenesis and/or chromatin structure. That group included 
transcription regulators (LARP7, TCF4, and GTF2I, Table 4) and an RNA editing enzyme 
(ADAR, Table 4).  
 
Verification of nucleolar enrichment of LARP7 and TCF4. Previously published proteomic 
studies of human cell lines of various origins did not report LARP7 or TCF4 to be nucleolar (24, 
48, 49). Moreover, immunofluorescence analysis of several other human cell lines did not 
support their nucleolar localization either (http://www.proteinatlas.org/). Therefore, in the 
developing rat brain, the apparent nucleolar enrichment of LARP7 and TCF4 were further 
examined using specific antibodies. First, western blot analysis of the nucleolar- and the whole 
nuclear lysates of the P7 cerebral cortex confirmed nucleolar enrichment of either protein (Fig. 
4G). In addition, nucleolar enrichment of the established ribosomal biogenesis factor EMG1 was 
also confirmed by western blotting (Fig. 4G).  
Second, immunofluorescence analysis of P7 rat brain sections revealed a strong 
nucleolar-like signal that was obtained with the anti-LARP7 antibody (Fig. 5A-F). In the 
neocortex and the hippocampus, nucleolar presence of LARP7 was observed in neurons but not 
in non-neuronal cells as determined by co-staining for the neuronal marker NeuN (Fig. 5A, E, 
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data not shown). Its nucleolar character was also confirmed by co-stainings for the nucleolar 
markers Npm and UBF (Fig. 5B, C, F). In addition, a diffused LARP7 signal was observed in the 
nucleoplasm (Fig. 5A-F). A similar pattern of LARP7 immunofluorescence was found in other 
analyzed structures including the thalamus (data not shown).  
Also, cultured rat neurons displayed nucleolar enrichment of LARP7 (Fig. 5G,H). 
However, as compared to cells from brain sections, stronger nuclear signal was observed in 
cultured cells. Conversely, in cultured rat primary astrocytes, no nucleolar enrichment was 
observed despite a strong nuclear signal of LARP7 (Fig. 5I). Therefore, nucleolar accumulation 
of LARP7 appears to be neuron-specific and may be sensitive to culture conditions.   
When cortical neurons were imaged at high magnification, diffused- and fine granular 
staining of LARP7 was visible throughout the nucleus (Fig. 5J). Such a distribution is consistent 
with a previously proposed role of LARP7 in regulation of RNA-Polymerase-2 (50-52). In the 
nucleolus, LARP7 signal only partially overlapped with that of Npm, suggesting its absence 
from the Npm-positive granular component of the nucleolus (GC) (Fig. 5J) (1). Conversely, 
LARP7 appeared to co-localize with fibrillarin which marks the dense fibrillar component (DFC) 
of the nucleolus where rRNA genes are transcribed and where their primary transcripts 
undergoes initial processing (Fig. 5J) (1).   
 
The transcriptional inhibitor Actinomycin D (ActD) led to nucleoplasmic release of Npm 
but not LARP7 suggesting that rRNA-protein interactions are dispensable for its nucleolar 
localization (Fig. 5H). In ActD-treated neurons, LARP and fibrillarin separated into apparently 
overlapping structures that were highly similar to nucleolar caps (Fig. 5J) (53). Hence, the 
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LARP7-containing caps resemble the previously reported light nucleolar caps (LNC) which are 
also known to sequester several snoRNAs (53).  
 
Unfortunately, in brain section, immunofluorescence analysis with the anti-TCF4 
antibody was not conclusive due to a very bright staining of the blood vessels and the 
extracellular matrix (data not shown). These signals which likely represent non-specific staining 
prevented conclusive observations of any staining from inside the cells. However, a specific 
signal was obtained in cultured primary rat brain cells suggesting perikaryal and nuclear 
presence of TCF4 (Fig. 6). In cortical- and hippocampal neurons as well as astrocytes, the 
nuclear signal was concentrated in the nucleolus (Fig. 6A-C). Besides nucleolus, both a diffuse- 
and a fine granular signal appeared throughout the nucleoplasm and in the perikarya (Fig. 6A-D). 
Hence, only a relatively minor fraction of cellular TCF4 may reside in the nucleolus.  
In nucleoli of cortical neurons, TCF4 overlapped nearly completely with fibrillarin but 
only partially with Npm or UBF (Fig. 6D). As in the case of LARP7, ActD did not trigger 
nucleoplasmic release of TCF4 which, instead, appeared sequestered in nucleolar cap-like 
structures (Fig. 6D). However, the TCF4-containing caps were fibrillarin-negative but UBF-
positive suggesting they were the fibrillar caps that sequester various component of the Pol1 
machinery including UBF (53). Thus, at least in rat cortical neurons, LARP7 and TCF4 appear to 
be concentrated in the DFC compartment of the nucleolus and undergo nucleolar cap 
sequestration after inhibition of Pol1. However, they segregate into distinct types of caps which 
may suggest different roles at the early stages of ribosomal biogenesis.  
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Requirement of LARP7 for ribosomal biogenesis. To test the role of LARP7 in ribosomal 
biogenesis, three different shRNAs against rat LARP7 were designed. When overexpressed in 
hippocampal neurons, these constructs reduced expression of endogenous LARP7 (Fig. 7A). 
Importantly, in transfected neurons, shRNAs against LARP7 prevented nucleolar staining with 
the LARP7 antibody further confirming specificity of the nucleolar signal (Fig 7A). Moreover, 
each of these constructs reduced perikaryal ribosome content by 22-40% as compared to a 
control shRNA (Fig. 7B-C). As reduction in ribosome content is expected to compromise protein 
synthesis activity, perikaryal accumulation of nascent peptides was monitored in LARP7-
deficient neurons using co-translational labeling with puromycin  (Fig. 7D-E). Indeed, shLAR7 
reduced general protein synthesis. However, the observed declines by 50-65% were greater than 
those in ribosome content (Fig. 7D-E). The effects of shLARP7 were compared to those of 
knocking down EMG1. EMG1 deficiency is a cause of Bowen-Conradi syndrome that combines 
neurodevelopmental delay and microcephaly. Two different shRNAs against EMG1 reduced 
ribosome content and protein synthesis by 32-40% and 30-36%, respectively (Fig. 8). Thus, 
knockdowns of LARP7 and EMG1 produce similar anti-ribosomal effects. However, 
translational inhibition was stronger with shRNAs against LARP7. Therefore, at least in 
hippocampal neurons LARP7 is required for ribosomal biogenesis. It may also have additional 
functions in regulation of general protein synthesis.     
 
Potential role of TCF4 in ribosomal biogenesis. To achieve loss-of-function of TCF4, two 
mutant forms of human TCF4 were overexpressed in cultured cortical neurons (Fig. 9A). These 
mutants (R580W and R582P ) disrupt the bHLH domain producing dominant-negative effects 
against wtTCF4 and the related members of the E-box family (35). Moreover, these mutants 
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cause a neurodevelopmental disease, PTHS which may also result from TCF4 
haploinsufficiency. After overexpressing the mutants for 3 days, perikaryal ribosome content 
was reduced by 20% or 15% as compared to empty vector (EV) or wtTCF4, respectively (Fig. 
9B-C). Similar reductions of general protein synthesis were also observed (Fig. 9D-E). These 
findings suggest that in hippocampal neurons TCF4 and/or its relatives from the E-box family of 
transcription factors play a role in ribosomal biogenesis.  
 
Discussion 
 Quantitative proteomic analysis uncovered several hundred proteins that are enriched in 
nucleoli of the cerebral cortex of neonate rats. Due to limitations of the applied methodology, it 
is likely that in many cases the nucleolar enrichment was underestimated. Thus, protein and 
peptide ratios derived from the multiplexed quantification (iTRAQ or TMT) of highly 
complicated mixtures are known to be distorted due to the interference from the co-fragmenting 
ions. High fold changes tend to be substantially underestimated, and, in consequence, the 
distribution of peptide/protein ratios is artificially narrowed (54). This effect might be dealt with 
using several methods. They are, however, either moderately effective (computing isolation 
specificity, fractionation) or costly in terms of protein identification efficiency (12-22% 
reduction of non-redundant protein identifications when isolation window is narrowed or 
additional MS3 fragmentation is employed). Increasing the accuracy of protein ratio at the 
expense of proteome coverage might be in some cases a prudent solution. However, this study 
was more focused on the enrichment/depletion status of proteins than on actual protein ratio and 
was also aiming at possibly comprehensive protein sequencing. Therefore the iTRAQ ratio 
compression was considered acceptable, and the assessment of accurate protein ratios was left 
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for the follow-up experiments. However, it is possible that the currently used proteomic 
approach missed a significant number of proteins that are enriched in brain cell nucleoli.  
 
Despite these limitations, the emerging nucleolar proteome landscape of the cerebral 
cortex of neonate rats suggests that ribosomal biogenesis remains active during postnatal stages 
of brain development. In addition, the importance of nucleolar contributions to 
neurodevelopment is suggested by human phenotypes that are associated with 16 proteins that 
are enriched in cerebro-cortical nucleoli including the ribosomal biogenesis factor EMG1, the 
RNA binding protein LARP7, and, the transcription factor TCF4. 
 
Surprisingly, only 106 of 286 human ribosomal biogenesis factors were represented by 
rodent homologs among all Nucleolus-enriched proteins from rat brain (including 643 proteins 
with significant Nucleolus-enrichment and 102 proteins with Nucleolus-enrichment trends that 
were supported by the Nucleolus-classifier). Such observations suggest a unique organization of 
the ribosomal biogenesis pathway in brain cells, including neurons. That concept is consistent 
with a report that in mouse brain there are different species of rRNA processing intermediates 
than in mouse kidney (55). In addition, as brain ribosomal production is relatively rapidly down-
regulated during the maturation phase of neurodevelopment (56-58) (Slomnicki and Hetman, 
unpublished results), lesser number of ribosomal biogenesis factors may be required to satisfy 
reduced needs for new ribosomes. In contrast, in proliferating cells, many additional 
enzymes/regulators may be necessary to maximize rate of ribosome synthesis.  
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Overall, the overlap between nucleolar proteomes of the brain and proliferating cells was 
relatively limited. For instance, when the list of putative brain nucleolar proteins with at least 
1.3-fold No/Nu enrichment was compared to 344 such proteins from human HCT116 colon 
carcinoma cells (24), only 114 proteins were found in both data sets. On that short list, the 
overrepresented GO_BPs were mostly related to ribosomal biogenesis and RNA metabolism.  
 
In addition, the nucleolus-enriched brain proteome was compared to non-quantitative 
data sets of 726 or 873 nucleolar proteins from human cervical carcinoma HeLa- or human T-
cell lymphoma Jurkat cells, respectively. The overlaps of 192 or 189 proteins were observed for 
each comparison (48, 49). The most highly enriched GO_BPs among the shared proteins were 
related to ribosomal biogenesis and RNA metabolism. Enrichment was also found for GO_BPs 
that are related to chromatin organization. When 263 brain-unique components of the nucleolar 
proteome (e.g. not present in either HeLa or Jurkat data sets) were analyzed for GO_BP 
enrichment, chromatin organization- but not ribosomal biogenesis remained overrepresented. 
The GO_BP term “chromosome organization” was associated with 21 proteins that were found 
in brain nucleoli but not in any other of the three nucleolar data sets from human cell lines (Table 
S4). Overall, it appears that nucleoli of mostly post-mitotic brain cells and proliferating cells 
share various proteins of the ribosomal biogenesis pathway and chromatin organization 
machinery. However, in brain cell nucleoli, relative representation of ribosomal biogenesis 
decreases. Conversely, the contribution of chromatin organization increases, including the 
appearance of brain nucleolus-specific chromatin components and modifiers. Therefore, brain 
cell nucleoli may participate not only in producing ribosomes but also in regulating chromatin 
structure. Alternatively, nucleolar chromatin structure may be more regulated and/or have 
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relatively greater modulatory effect on brain cell ribosome production. Finally, the previously 
demonstrated nucleolar association of specifically regulated chromatin domains may be greater 
in brain cells increasing co-purification of chromatin organization proteins together with the 
nucleoli (59, 60).  
 
Several putative nucleolar proteins from the developing brain are associated with human 
neurodevelopmental diseases including three established ribosomal biogenesis factors and a 
ribosomal protein (Table 4). A question that emerges from such an association is whether the 
nucleolus contributes to neurodevelopment? Rapidly proliferating cells are considered to be most 
sensitive to deficiencies in ribosome biogenesis (61, 62). Hence, neuroprogenitor proliferation 
could be impaired if ribosome production declines. In addition, the nucleolar/ribosomal stress 
response could initiate p53-dependent apoptosis eliminating neuroprogenitors with suboptimal 
ribosome production (13). Such a defective neurogenesis could account for microcephaly that is 
observed in 9 out of 16 syndromes that are associated with mutations of the putative nucleolar 
brain proteins (Table 4).  
 
In addition, neuronal maturation is associated with intense neurite outgrowth that 
involves ribosomal biogenesis (10)(Slomnicki and Hetman, unpublished results). In fact, on 
postnatal day 7, when the nucleolar fractions of the cerebral cortex were obtained, there is 
neuritic growth and maturation but little neurogenesis in that region of the rodent brain (63). 
Therefore, it is tempting to speculate that ribosome depletion and consequent dysregulation of 
neuronal maturation including reduced neuritic morphogenesis contribute to at least some 
neurodevelopmental diseases that are associated with the nucleolar proteins.  
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The newly identified components of neuronal nucleolar proteome include the RNA 
binding protein LARP7 and the E-box transcription factor TCF4 whose deficiencies in humans 
are associated with cognitive impairment and microcephaly (64, 65). By binding and stabilizing 
a small non-coding RNA, 7SK RNA, LARP7 negatively regulates the general Pol2 transcription 
elongation factor P-TEFb as well as the transcription factor HMGA1 (50-52). However, it is 
unclear whether dysregulation of these transcription factors contributes to pathology of Alazami 
syndrome that besides sever cognitive impairment also includes dwarfism (64). In fact, such a 
pathogenic contribution appears counterintuitive as excessive activity of P-TEFb or HMGA1 
may underlie increased proliferative growth following transformation (see discussion in (64)). 
Our findings that neuronal LARP7 is required for ribosomal biogenesis suggest that, at least, 
neurological symptoms of Alazami syndrome are caused by translational deficits and/or 
nucleolar stress.  
 
 Similarly to Alazami syndrome, little is known about pathogenic mechanisms that 
underlie PTHS. The disease is caused by heterozygous deletions or point mutations disrupting 
the function of TCF4 by a loss of one active allele, generation of hypomorphic alleles or 
dominant negative effects (35). Our data indicate that the PTHS-associated dominant-negative 
mutants of TCF4 moderately reduce ribosomal biogenesis and general protein synthesis. While 
future experiments are needed to clarify role of TCF4 in neuronal ribosome biogenesis, it is 
noteworthy that ribosomal proteins as well as many trans-acting factors of ribosome synthesis 
and nucleolus-associated proteins were shown to have their gene regulatory regions bound to 
TCF4 (66). In addition, the GO_BP term “ribosomal biogenesis” appeared to be overrepresented 
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among genes that were down-regulated after TCF4 knockdown in human neuroblastoma cells 
(67). In proliferating cells, many of these genes, as well as rDNA, are regulated by E-boxes that 
interact with c-Myc (68, 69). Conversely, TCF4 and/or a TCF4-related transcription factors may 
regulate ribosomal biogenesis by engaging the same E-boxes in postmitotic and/or differentiating 
cells.  
Putative proteins of the nucleolar brain proteome include 7 chromatin organization 
factors that are also associated with neurodevelopmental diseases. At least  for one of such 
factors, the cohesin SMC1A, deficient rRNA transcription has been proposed as a mechanism 
that could explain cohesonipathy pathology in non-dividing cells including neurons (70, 71). Of 
note, two other cohesinopathy-associated proteins including NIPBL and SMC3 were also 
enriched in cerebro-cortical nucleoli, albeit less than 1.3 fold (OMIM #122470 and #610759, 
Table S2). Critical role of chromatin organization factors in rRNA transcription is not limited to 
cohesins but has been also reported for the chromatin remodeling complexes B-WICH and 
FACT whose various components are enriched in brain cell nucleoli(72, 73) (Table S2). Future 
studies are needed to investigate the role of nucleolus-enriched chromatin organizers in ribosome 
synthesis in the brain.  
 Taken together, the presented proteomic characterization of the nucleoli from the cerebral 
cortex of neonate rats supports the notion that the nucleolus is critical for neurodevelopment. 
Ribosomal biogenesis appears as top candidate function of the nucleolus through which it may 
affect formation and maturation of the nervous system. Disruption of ribosomal biogenesis by 
genetic and/or environmental factors may contribute to pathogenesis of various 
neurodevelopmental disorders. Finally, the current description of the nucleolar proteome offers a 
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starting point to examine brain cell specific regulation of ribosomal synthesis, brain ribosome 
diversity, and nucleolar impact on neuronal chromatin organization and genomic maintenance.  
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Figure Legends 
Figure 1. Preparation of nucleolar proteins from the cerebral cortex of neonate rats. The 
schematic presents the nucleolar isolation procedure. First, whole nuclei were isolated from the 
neocortex of P7 rats. After sonication, the released nucleoli were purified by ultracentrifugation; 
some intact nuclei were still present in such preparations (see Materials and Methods for more 
details).  
 
Figure 2. Morphology of isolated nuclei and nucleoli from the cerebral cortex of neonate 
rats. A-B. Phase contrast micrographs of unfixed nuclei (arrows) and nucleoli (arrowheads). C-
D, Isolated nucleoli (C) or nuclei (D-E) were fixed and immunostained as indicated; DNA was 
visualized by counterstaining with Hoechst-33258. In isolated nucleoli(C), or, in intact nuclei 
(D-E), nucleolar markers fibrillarin and nucleophosmin (Npm) remained nucleolar suggesting 
good preservation of the nucleolus throughout the fractionation procedure. In D, the isolated 
whole nuclei were co-immunostained for the neuronal nuclear marker NeuN and the Npm. The 
arrow points a NeuN-reactive (i.e. neuronal) nucleus; the arrowhead marks a non-neuronal 
nucleus. Note that in neuronal nuclei, nucleoli were usually larger than in non-neuronal nuclei. 
 
Figure 3. Enrichment of nucleolar marker proteins in isolated nucleoli from the cerebral 
cortex of neonate rats. Enrichment of nucleolar proteins in nucleolar preparations (No) was 
verified by Western blotting. A, Note that nucleolar proteins including fibrillarin, Npm and UBF 
were more abundant in No lysates than in total nuclear lysate (Nu) as compared to a nuclear 
marker NeuN. B, Averages±SEM of such NeuN-normalized enrichments from 8 independent 
preparations are presented on the graph. C, Nucleolar enrichment was further evaluated by 
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western blotting for markers of other cellular components including microfilaments (actin), 
microtubules (tubulin), mitochondria (Tom20) and endoplasmic reticulum (calreticulin). When 
compared to total cortical- (TL), or, whole nuclear lysates (Nu), the fibrillarin-normalized 
content of these potential contaminants was lowest in nucleolar lysates (No). Similar results were 
observed with lysates from two independent experiments/isolations. Band intensities were 
quantified by densitometry and normalized against intensity of NeuN-(B) or fibrillarin (C) 
signals.  
 
Figure 4. Analysis of the nucleolar proteome from the developing rat cerebral cortex. A, 
Three independent sets of total nuclear/nucleolar protein samples from the cerebral cortex of P7 
rats were analyzed using quantitative iTRAQ proteomics. Filter Aided Sample Preparation 
(FASP) was applied to obtain peptides that were tagged using an 8-plex iTRAQ system for 
quantitative LC/MS analysis. B, The pie chart illustrates the numbers of proteins with differential 
abundance in the nucleolus (No). C, Distribution of relative No enrichments among 1,130 
differentially localized proteins. Numbers over the bars correspond to numbers of proteins in 
each enrichment bin. D, Increased No enrichment correlates with greater fraction of proteins that 
are associated with the gene ontology (GO) term “nucleolus”. Numbers over the bars correspond 
to numbers of proteins that are passing each enrichment threshold. E-F, Gene ontology (GO) 
analysis of 504 mapped proteins whose nucleolar enrichment was at least 1.3 fold. The 
significance threshold for GO enrichment was FDR<0.05. The pie charts present fractions of No 
proteins that were assigned to enriched GO_CC- (cellular compartment, E) or GO_BP 
(biological process, F) categories. Related terms were grouped together; overlapping GO 
assignments were avoided to accurately determine the fraction of unclassified proteins. More 
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details about GO enrichment are in Tables 1-3. G, Nucleolar enrichment of the candidate 
nucleolar proteins EMG1, LARP7 and TCF4 was verified by Western blotting. The established 
ribosomal biogenesis factor EMG1 was used as an additional control. Note that relative 
abundance of each of these three proteins is greater in nucleolar lysates as compared to whole 
nuclear lysates resembling nucleolar enrichment of fibrillarin. Similar trends were observed in 
two independent experiments/isolations.   
 
Figure 5. Nucleolar presence of the RNA-binding protein LARP7 in forebrain neurons. A-
F, LARP7 immunofluorescence in P7 rat brain sections that were cut through the dorsal 
hippocampus; co-stainings with neuronal- or nucleolar markers are shown as indicated; DNA 
was counterstained with Hoechst-33258; in D, LARP7 antibody was replaced by control rabbit 
IgG. Representative micrographs of cells from the neocortical layer V (A-D) and the 
hippocampal field CA1 (E-F, the pyramidal layer) are shown. Both nuclear and nucleolar signals 
of LARP7 are visible in neurons from each region. G-J, LARP7 Immunostaining in cultured 
primary rat brain cells including DIV6 cortical neurons (G, J), DIV7 hippocampal neurons (H) 
and DIV10 astrocytes (I). Note nucleolus-like staining in neurons but not astrocytes; both cell 
types display nuclear presence of LARP7. In J, representative nuclear profiles are shown 
following 6h treatment with 0.1% DMSO (vehicle) or 1 μM ActinomycinD (ActD). In vehicle-
treated cells, overlapping stainings of LARP7 and fibrillarin suggest LARP7 localization to the 
dense fibrillar component (DFC) of the nucleolus. After transcriptional inhibition, Npm but not 
LARP7 or fibrillarin were released into nucleoplasm; moreover, the persistent overlap of LARP7 
and fibrillarin indicates co-localization to light nucleolar caps which sequester early rRNA 
processing factors including snoRNAs (see text for details).  
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Figure 6. Nucleolar presence of the transcription factor TCF4 in primary cultures of 
forebrain neurons and astrocytes. Cultured rat brain cells were immunostained for TCF4 and 
the nucleolar markers as indicated. A, Representative images depicting TCF4 
immunofluorescence in DIV6 cortical neurons. Both diffused and fine granular signals were 
observed in the nucleus and the perikaryon. In addition, nucleolus-like structures were detected 
(arrows). A’, No signal was observed with a control IgG. Similar TCF4 staining pattern 
including nucleolar-like structures was found in DIV7 hippocampal neurons (B) and in DIV10 
primary astrocytes (C). D, Representative nuclear profiles of DIV6 cortical neurons following 6h 
treatment with 0.1% DMSO (vehicle) or 1 μM ActinomycinD (ActD). Note that the TCF4 signal 
shows the most extensive overlap with fibrillarin and only a partial overlap with Npm or UBF 
suggesting its localization to the transcriptionally active DFC. After transcriptional inhibition, 
TCF4, fibrillarin and UBF remained associated with the nucleolus. Note that fibrillarin and 
TCF4 segregated into distinct structures (indicated by a star) while UBF and TCF4 overlapped 
(indicated by a hash sign). Such a segregation pattern resembles fibrillar caps that sequester core 
components of the nucleolar transcription machinery (see text for details).   
 
Figure 7. Reduced neuronal ribosome content and inhibition of protein synthesis after 
knockdown of LARP7 in hippocampal neurons. DIV4 (A) or DIV6 (B-E) rat hippocampal 
neurons were co-transfected with expression vectors for RFP and shRNAs against LARP7 or a 
control shRNA (shLuc, 0.2 + 0.6 μg of plasmid DNAs/2*105 neurons, respectively); in D-E, 0.1 
μg EGFP expression vector was used instead of RFP. A, Representative images of transfected 
neurons (i.e. RFP-positive) that were fixed and immunostained for endogenous LARP7 at 72h 
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post-transfection (arrows). Note that shLARP7 constructs reduced expression of endogenous 
LARP7 including disruption of the LARP7 signal in the nucleoli. B-C, After 3 days, perikaryal 
ribosome content was evaluated in RFP-positive cells by measuring intensity of ribosomal 
staining with NeuroTrace Green. For quantification, the ribosomal signal was normalized against 
DNA content in the nucleus as determined by counterstaining with Hoechst-33258. B, 
Representative images of transfected (i.e. RFP-positive) neurons whose ribosomes were stained 
with NeuroTrace Green (arrows). C, Quantification of ribosomal content in transfected neurons. 
shRNAs reduced mean ribosomal content. Data represent means ±SEM of at least 72 cells from 
three independent experiments; ***, p < 0.001. D-E, Three days after transfection, O-propargyl-
puromycin (OPP) was added to the culture medium to label nascent peptides which were 
visualized after fixation by fluorescent Click iT chemistry that was followed by GFP 
immunostaining. D, Representative images of transfected (i.e. GFP-positive) neurons with 
nascent peptide accumulation (arrows). E, Nascent peptide accumulation in the perikarya was 
reduced by shLARP7 constructs suggesting global translation deficiency. Data represent means 
±SEM of at least 54 individual cells from two independent experiments; ***, p < 0.001. Signal 
specificity controls for NeuroTrace staining of ribosomes (loss of staining after RNase A 
treatment) and OPP labeling of nascent peptides (loss of signal in cycloheximide-treated 
neurons) are presented in Figure S3.  
 
Figure 8. Reduced neuronal ribosome content and inhibition of protein synthesis after 
knockdown of EMG1 in hippocampal neurons. A, COS7 cells were co-transfected with 
expression vector for EMG1-EGFP together with the expression vector for β-galactosidase (β-
gal) and shRNAs against EMG1 or control shRNA (shLuc, 1 + 1 + 2 μg of plasmid DNA/60 mm 
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plate). Western blot for GFP revealed efficient knockdown of the target 48 h post transfection; 
the membrane was also probed for β-gal to ensure similar transfection efficiency.  B-E, DIV6 rat 
hippocampal neurons were transfected and stained as described for experiments in Fig. 7B-E. B-
C, Knockdown of EMG1 reduced mean ribosomal content in the perikarya. Data represent 
means ±SEM of at least 58 cells from three independent experiments; ***, p < 0.001. D-E, 
Knockdown of EMG1 reduced general protein synthesis. Data represent means ±SEM of at least 
48 cells from two independent experiments, ***, p < 0.001.   
 
Figure 9. Reduced neuronal ribosome content and inhibited protein synthesis after 
overexpression of the PTHS-associated dominant-negative mutant form of TCF4. DIV3 (A) 
or DIV6 (B-D) rat hippocampal neurons were co-transfected with expression vectors for human 
TCF4 including its wt- and two PTHS-associated mutant variants together with expression 
constructs for β-galactosidase (β-gal, A) or RFP (B,C) or EGFP (D,E) (0.4+0.2 μg of plasmid 
DNAs/2x105 neurons, respectively). A, After 24 h, human TCF4 mRNA levels were determined 
by qRT-PCR and normalized to β-gal mRNA. Human TCF4 was detected in neurons that 
received TCF4 plasmids but not the empty vector control. B-E, After 3 days, perikaryal 
ribosome content (B-C) and general protein synthesis (D-E) were evaluated as described for Fig. 
7. The mutants but not the wt reduced mean ribosomal content and general protein synthesis. 
Data represent means ±SEM of at least 80 cells from five independent experiments (C) or 68 
cells from three independent experiments (E); *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 
0.05.  
 
 
Table 1. The FDR-verified  enrichment of GO_CC categories 
Fold Enriched % List FDR Fold Enriched % List FDR
GO:0030684~preribosome 17.77 1.59 1.10E-04 3.36 0.26 NS
GO:0005730~nucleolus 7.73 16.47 2.94E-47 1.93 3.58 1.67E-13
GO:0000786~nucleosome 7.45 3.17 2.70E-06 2.32 0.86 0.001155
GO:0005840~ribosome 7.22 9.52 3.96E-24 2.52 2.90 5.58E-22
GO:0033279~ribosomal subunit 6.56 2.98 5.76E-05 2.51 0.99 8.55E-06
GO:0000792~heterochromatin 6.23 2.18 0.010759 2.22 0.68 NS
GO:0005681~spliceosome 4.66 3.97 6.36E-05 2.92 2.17 1.04E-21
GO:0000785~chromatin 4.38 4.96 3.13E-06 1.85 1.83 6.27E-05
GO:0005694~chromosome 3.13 8.13 3.42E-07 1.49 3.37 8.18E-04
GO:0044427~chromosomal part 2.72 5.95 0.002514 1.47 2.79 0.01671
GO:0005604~basement membrane 6.72 3.37 3.71E-06 1.43 0.63 NS
GO:0044420~extracellular matrix part 5.34 3.37 1.21E-04 NE NE NE
GO:0005739~mitochondrion 2.47 22.42 3.12E-17 1.89 14.99 6.36E-66
* only organelle/structure/complex-specific  GO_CC categories are not shown
^ the analyzed list included 504 mapped IDs of proteins with at least 1.3 fold No enrichment; of them 433 had assigned GO_CC terms
~ the analyzed list included 3830 mapped IDs, of them 2865 had assigned GO_CC terms
NS, p>0.05
NE, not enriched
NUCLEOLUS^ NUCLEUS (all identified)~
GOTERM_CC_FAT*
Table 2. The FDR-verified  enrichment of GO_BP categories 
Fold Enriched % list FDR Fold Enriched % list FDR
GO:0042254~ribosome biogenesis 13.85 8.73 1.90E-23 2.69 1.70 4.1078E-13
GO:0006396~RNA processing 12.99 13.89 2.18E-33 2.36 5.80 5.7144E-39
GO:0006364~rRNA processing 11.50 6.15 0.005802 2.76 1.15 1.5491E-08
GO:0016072~rRNA metabolic process 11.02 6.15 0.007979 2.72 1.15 2.8768E-08
GO:0006412~translation 10.86 9.92 2.61E-30 2.60 4.67 2.3355E-38
GO:0034470~ncRNA processing 9.80 6.75 0.018929 1.67 1.49 NS
GO:0034660~ncRNA metabolic process 9.60 6.94 0.004574 1.88 2.14 2.82E-06
GO:0051276~chromosome organization 9.45 8.53 0.024588 1.53 3.47 0.0001808
GO:0006397~mRNA processing 9.12 6.35 0.031575 2.76 4.07 2.5363E-37
GO:0006333~chromatin assembly or disassembly 8.97 4.17 2.39E-07 2.38 1.46 4.48E-08
GO:0006325~chromatin organization 7.25 6.94 5.93E-06 1.62 2.87 9.0115E-05
GO:0006323~DNA packaging 7.05 3.97 8.79E-06 2.25 1.28 1.062E-05
GO:0016071~mRNA metabolic process 6.96 6.55 1.07E-05 2.55 4.33 8.101E-34
GO:0008380~RNA splicing 6.96 5.16 1.07E-05 2.98 3.37 3.5164E-35
GO:0006334~nucleosome assembly 6.55 3.17 2.39E-07 2.48 1.02 1.759E-05
GO:0031497~chromatin assembly 6.37 3.17 1.25E-07 2.47 1.04 1.1704E-05
GO:0034728~nucleosome organization 5.40 3.17 3.74E-04 2.38 1.02 7.316E-05
* all mitochdria related GO_BP categories were excluded as a potential contamination
^ the analyzed list included 504 mapped IDs of proteins with at least 1.3 fold No enrichment; of them 411 had assigned GO_BP terms
~ the analyzed list included 3830 mapped IDs, of them 2930 had assigned GO_BP terms
NS, p>0.05
NUCLEOLUS ^ NUCLEUS (all identified)~
GO_BP_FAT Term*
Table 3. The FDR-verified  enrichment of GO_MF categories 
Fold Enriched % List FDR Fold Enriched % List FDR
GO:0019843~rRNA binding 16.69 2.38 3.8E-08 3.07 0.42 0.030584
GO:0003735~structural constituent of ribosome 9.95 8.93 1.6E-28 2.90 2.48 4.82E-24
GO:0070035~purine NTP-dependent helicase activity 6.60 3.37 6.2E-06 2.31 1.12 3.67E-05
GO:0008026~ATP-dependent helicase activity 6.60 3.37 6.2E-06 2.31 1.12 3.67E-05
GO:0004386~helicase activity 5.69 4.37 3.1E-07 2.18 1.59 4.60E-07
GO:0005198~structural molecule activity 4.53 12.10 5.6E-20 1.93 4.91 3.91E-19
GO:0003723~RNA binding 3.83 15.28 1.7E-21 2.13 8.12 1.27E-44
GO:0042623~ATPase activity, coupled 3.14 4.17 1.8E-02 2.03 2.56 2.73E-10
GO:0000166~nucleotide binding 1.54 20.04 5.8E-03 1.87 23.11 1.85E-104
* mitochondrial protein-enriched  categories are not shown 
^ the analyzed list included 504 mapped IDs of proteins with at least 1.3 fold No enrichment; of them 398 had assigned GO_MF terms
~ the analyzed list included 3830 mapped IDs, of them 2881 had assigned GO_MF terms
NUCLEOLUS^ NUCLEUS (all identified)~
GOTERM_MF_FAT*
TABLE 4. Human counterparts of No-enriched rat brain proteins whose mutations cause neurodevelopmental diseases.  
Protein 
 
No/Nu 
  
Function 
 
Disease/neurological phenotype 
OMIM#/ 
(Reference) 
EMG1 1.66 Ribosomal biogenesis Bowen-Conradi Syndrome/microcephaly, developmental delay 211180 
RPL10 1.43 Structural protein of the ribosome X-linked microcephaly, growth retardation, and seizures (44) 
DKC1 2.07 Ribosomal biogenesis/telomere 
maintenance  
Dyskeratosis Congenita, X-Linked/learning difficulties, 
microcephaly, cerebellar hypoplasia 
305000 
EIF4A3 1.36 Ribosomal biogenesis, mRNA splicing 
and decay 
Richieri-Costa-Pereira Syndrome/developmental delay, learning 
disability, language delay/disorder 
268305 
 
FLNA 
 
1.63 
Actin regulation, negative regulation of 
PI3K signaling, negative regulation of 
Pol1, pre-rRNA processing  
Heterotopia, Periventricular, X-Linked Dominant/ seizures, cortical 
dysplasia 
300049 
SMC1A 1.42 Chromatid cohesion, general 
transcription regulation 
Cornelia De Lange Syndrome 2/microcephaly, mental retardation, 
dilated ventricles, seizures 
300590 
MCM4 1.93* Prevents DNA re-replication, maintains 
genomic stability 
Natural Killer Cell And Glucocorticoid Deficiency With Dna Repair 
Defect/microcephaly 
609981 
NSD1 1.3 Transcription factor and chromatin 
modifier 
Sotos Syndrome 1/ macrocephaly, ventriculomegaly, seizures, 
developmental delay, mental retardation, poor coordination 
117550 
CUL4B 1.31 DNA damage response  Mental Retardation, X-Linked, With Short Stature 300354 
PRKDC 2.2* DNA damage response Immunodeficiency 26 With Or Without Neurologic Abnormalities/ 
Microcephaly, mental retardation) 
615966 
ATRX 1.43 
 
Chromatin remodeling  Alpha-Thalassemia and/or Mental Retardation Syndromes, X-
Linked; Linked/mental retardation, microcephaly 
301040; 
309580 
 
 
LMNA 
 
 
1.54 
 
 
Nuclear envelop protein 
Charcot-Marie-Tooth Disease, Axonal, Type 2b1 (LMNA loss of 
function)/axonal atrophy in peripheral nerves, distal limb muscle 
weakness/atrophy due to peripheral neuropathy; Malouf Syndrome 
(heterozygous point mutation in LMNA, possible gain of 
function)/mental retardation 
605588; 
212112 
LARP7 2.05 Stabilizes 7SK ncRNA that inhibits the 
p-TEFb transcription factor 
Alazami Syndrome/ intelectual disability and microcephaly 615071 
 
TCF4 
 
2.23* 
 
Transcription factor 
Pitt-Hopkins Syndrome/postnatal microcephaly, cerebral atrophy, 
mental retardation, poor or absent speech development, seizures, 
hypotonia 
610954 
GTF2I 1.32 General transcription factor Williams-Beuren Syndrome/mental retardation, poor visual-motor 
integration, hypotonia, poor balance and coordination 
194050 
ADAR 1.47 RNA editing Aicardi-Goutieres Syndrome 6/atrophy of striatum, leukodystrophy, 
dystonia, tremor, loss of motor skils 
615010 
Shading: dark gray- ribosomal biogenesis-related proteins, light gray- chromatin organization/ genome maintenance-related protein, 
* Non-significant enrichment that was supported by the classifier  
TABLE 5. Human counterparts of No-enriched rat brain proteins whose mutations cause neurodegenerative diseases.  
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No/Nu 
 
Function 
 
Disease/neurological phenotype 
OMIM#/ 
(Reference) 
 
EWSR1 
 
1.9 
RNA binding protein, RNA splicing, 
ribosomal biogenesis 
Amyotrophic Lateral Sclerosis (45) 
 
TARDBP 
 
 
1.45 
DNA/RNA binding protein, RNA 
splicing 
Amyotrophic Lateral Sclerosis 10 With Or Without 
Frontotemporal Dementia; Als10 
612069 
 
LMNB1 
 
1.47 
 
nuclear envelop protein 
Leukodystrophy, Demyelinating, Adult-Onset, Autosomal 
Dominant (LMNB1 duplication); ADLD; cerebellar ataxia, 
cognitive decline, personality changes due to degeneration of the 
CNS white matter 
169500 
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